ProCE Banner Activity

Decoding HLA-DQA1*05 in IBD Therapy

Clinical Thought

Should you screen every patient with inflammatory bowel disease for HLA-DQA1*05? Here’s our take.

Released: March 02, 2022

Expiration: March 01, 2023

Share

Faculty

Marla Dubinsky

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric GI and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Icahn School of Medicine, Mount Sinai New York
New York, New York

Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by the American Gastroenterology Association.

ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Pharmaceuticals U.S.A., Inc.

Faculty Disclosure

Primary Author

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric GI and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Icahn School of Medicine, Mount Sinai New York
New York, New York

Marla Dubinsky, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer, Prometheus, Takeda, and UCB; funds for research support from AbbVie, Janssen, Pfizer, and Prometheus; has ownership interest and intellectual property rights in Trellus Health; and has received other financial or material support from Takeda.

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, AGAF, has disclosed that he has received consulting fees from 4D Pharma, AbbVie, Abivax, Alimentiv, Allergan, Amgen, Arena, AstraZeneca, Bacainn, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella, Celgene, Celltrion, ClostraBio, Enthera, F. Hoffmann-La Roche, Ferring, Galapagos, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic, Oppilan, OSE, Otsuka, Palatin, Pfizer, Progenity, Prometheus, Protagonist, Q32 Bio, Redhill, Rheos, Salix, Seres, Shire, Sienna, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva, Thelium, Theravance, TLL Pharma, USWM Enterprises, Ventyx, Viela Bio, Vivante, and Vivelix; has received funds for research support from Janssen, Pfizer, Takeda, and Theravance; and has ownership interest in Ventyx and Vivante.